Send to

Choose Destination
Oncoimmunology. 2013 Feb 1;2(2):e22893.

Engineering effective T-cell based antitumor immunity.

Author information

Department of Pharmacology and Genetics; Medical University Innsbruck; Innsbruck, Austria.


The adoptive transfer of synthetic siRNA-mediated cblb-depleted autologous CD8+ T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augment the effectiveness of adoptively transferred immune cells.


RNA interference; cancer immunotherapy; cblb; engineered T cells; reinforced anti-tumor functions

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center